Key result
Neprilysin inhibitors lower heart failure events and mortality while modestly lowering blood pressure, but studies have not shown evidence of improvement in kidney-related parameters.
Why the study?
Although neprilysin inhibitors show promising benefit in heart failure, data on their effects on renal function remain limited.
Do neprilysin inhibitors improve renal function compared to ACE inhibitors or ARBs in patients with heart failure or hypertension?
Do neprilysin inhibitors improve renal function compared to ACE inhibitors or ARBs in patients with heart failure or hypertension?
Answers are grounded in this paper and cite their sources.
While neprilysin inhibitors lower heart failure events and blood pressure, current evidence does not demonstrate a significant improvement in kidney-related parameters compared to standard therapies.
Cardiovascular disease is one of the major causes of mortality throughout the world. Renin Angiotensin blockers are well known for their beneficial effects in patients with heart failure. New emerging medications like neprilysin inhibitors have shown trend towards positive benefit in patients with heart failure. Data on the effect on renal function is still limited. Through this article, we are reviewing multiple randomized clinical trials involving Neprilysin and summarize the renal effects of the medicine.
No takes yet. Share an insight, caveat, or question.
Girish Singhania (2019) conducted a review in Heart failure and hypertension (n=43,368). Neprilysin inhibitors vs. ACE inhibitors, ARBs, or placebo was evaluated on Renal function and blood pressure. Neprilysin inhibitors lower heart failure events and mortality while modestly lowering blood pressure, but studies have not shown evidence of improvement in kidney-related parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: